For chronic migraine, botulinum type A injections are superior to placebo after three months of therapy.
Higher levels of serum 25-hydroxyvitamin D may be associated with lower risk for migraine headaches.
Common and rare neurologic manifestations associated with fibromuscular dysplasia include migraine-type headaches, tinnitus, ischemic stroke, and transient ischemic attack.
Hemicrania continua, one of the trigeminal primary headaches, causes intense unilateral pain for ≥3 months.
A review of patients' medical charts was performed to determine characteristics of headache in pseudotumor cerebri syndrome in adolescents.
Researchers and pain experts formulated guidelines for the use of onabotulinumtoxinA for the management of chronic migraine.
The primary efficacy endpoint was the mean change from baseline in the monthly average number of headache days of at least moderate severity during the 3-month treatment period.
Fremanezumab may be efficacious for the prophylaxis of chronic migraine in individuals with comorbid migraine and moderate/moderate to severe depression.
DFN-11, a 3 mg subcutaneous sumatriptan autoinjector, may provide an alternative to SC sumatriptan 6 mg for individuals with episodic migraine.
GammaCore Sapphire, a new non-invasive hand-held device for migraine and episodic cluster headache treatment, has been made available by electroCore.
The investigators sought to evaluate whether early-life traumatic experiences, stressful life events, and alexithymia are associated with chronic migraine and medication overuse headache.
For patients with episodic migraine, galcanezumab is better than placebo for reducing migraine headache days.
Individuals with chronic vs episodic migraine may be more likely to experience chronic back pain, chronic pain, neck pain, anxiety, and depression.
Researchers deployed a survey to determine the extent of pain, psychiatric, endocrine, and neurologic comorbidities in patients with chronic or episodic migraine.
For individuals with migraine frequency of 4 to 14 episodes per month, prophylactic medications and analgesics are required.
For patients with chronic migraine, onabotulinumtoxinA was shown to have a better outcome.
Both erenumab and fremanezumab are currently under review by the FDA for the treatment of migraine.
Clinicians need to consider treatments for episodic migraine that may be contraindicated if a patient also has cardiovascular disease.
Future predictive models may need to include other migraine risk factors to enhance predictive accuracy.
Acupressure is not a beneficial adjunctive therapy to sodium valproate for the treatment of chronic migraine with aura.
More targeted injection sites may improve efficacy and the overall patient experience in chronic migraine.
Vestibular migraine often goes unrecognized particularly in the absence of headache.
The majority of centers follow protocols for administration of onabotulinumtoxinA.
Headache, dizziness, and psychological factors in patients with vestibular migraine were alleviated by vestibular rehabilitation.
A growing body of research indicates a number of shared features between chronic migraine and temporomandibular disorders.
In chronic migraine and medication overuse, those who frequently relapse into overuse after withdrawal have a worse clinical and psychological profile than patients who relapse less frequently.
During headache, patients with chronic migraine had greater activity in the right anterior hypothalamic region than patients with episodic or no migraine.
Treatment with the monoclonal antibody erenumab reduced the number of monthly migraine days experienced in patients with episodic migraine.
Women with a history of migraine are at increased risk for developing hypertension.
The study found a strong link between chronic migraine and psychological symptoms and beliefs that contribute to disability.
Neurology Advisor Articles
- Survival in Parkinson Disease Dependent on Parkinsonian Type, Characteristics
- Case Study Report: Herbal Supplement Kratom Associated With Neonatal Abstinence Syndrome
- Mobile Health Apps for Headache: An Ongoing Search for Clinical Relevancy
- Behavioral Therapies May Treat Headache and Post-Concussive Symptoms
- Young Fresh Frozen Plasma Infusion Safe, Feasible in Alzheimer Disease
- Alemtuzumab Linked to Clinical and MRI Disease Remission in Multiple Sclerosis
- Very Early Mobilization After Stroke Does Not Improve Survival Over Usual Care
- Cognitive Decline Worsens With Memantine, ChEIs in Patients With Alzheimer's
- Levodopa Inhalation Powder Approved for Parkinson Disease
- Hematology Indicates Need for Thrombophilia Test in Children With Migraines
- Ocrelizumab Reduces Upper Extremity Disability Progression Risk in PPMS
- Cerebellar Stimulation May Help Improve Gait and Balance Recovery in Stroke
- Increased Dementia Risk in Older Adults With Down Syndrome
- Psychotherapy May Reduce Frequency of Nonepileptic Seizures
- Should CHA2DS2-VASc Be Reassessed More Frequently to Improve Stroke Prevention in Afib?